Comparison of Efficacy of Ceftazidime/Averbactam and Polymyxin B in the Treatment of Carbapenem-Resistant Pseudomonas Aeruginosa Infection
Objective To compare the clinical efficacy of ceftazidime/averbactam(CAZ/AVI)and polymyxin B(PMB)in the treatment of carbapenem-resistant Pseudomonas aeruginosa(CRPA)infection.Methods A retrospective analysis was conducted on 75 patients with CRPA infection admitted to the hospital from January 2019 to December 2022.They were divided into the CAZ/AVI group(n=48)and the PMB group(n=27)according to different treatment plans.The patients in the CAZ/AVI group received intravenous infusion of CAZ/AVI,while the patients in the PMB group received intravenous infusion of PMB.Results The clinical cure rate and bacterial clearance rate in the CAZ/AVI group were significantly higher than those in the PMB group(54.17％vs.29.63％,66.67％vs.37.04％,P＜0.05),but the incidence of skin pigmentation in the CAZ/AVI group was significantly lower than that in the PMB group(0 vs.48.15％,P＜0.001).There was no significant difference in the course of treatment,combination therapy,and 30 d mortality rate between the two groups(P＞0.05).Conclusion The clinical efficacy and bacterial clearance rate of CAZ/AVI in the treatment of CRPA infection patients are better than PMB,with fewer adverse reactions.
万方数据
维普
